Icahn School of Medicine at Mount Sinai

Mount Sinai School of Medicine

Other

United States of America, As Represented by the Secretary of Agriculture

Memorial Sloan Kettering Cancer Center

St. Jude Children's Research Hospital

National Institutes of Health, a Component of the US Dept. of Health & Human Services

Medimmune Vaccines, Inc.

Aviron

University of Kentucky Research Foundation

The Salk Institute for Biological Studies

Sanford-burnham Medical Research Institute

Worcester Foundation for Experimental Biology

The Mount Sinai Medical Center

New York University

Peter M Palese

Adolfo Garcia-Sastre

Florian Krammer

Thomas Muster

Robert G Webster

Kelly M Lager

Richard John Webby

Juergen A Richt

Dmitriy Zamarin

Robert O'Neill

John F Steel

Christopher Basler

Robert E O'Neil

Anice C Lowen

Taia T Wang

Yuman Fong

George G Brownlee

Gene Tan

Megan Ermler

Megan Shaw

Sudhir Agrawal

Jedd David Wolchok

Paul C Zamecnik

Ronald N Harty

Hans-Heinrich Hoffmann

Teddy John Wohlbold

Josef M Leiter

Mark Krystal

Jeffrey D Parvin

Adolfo Garc&iacute;a-Sastre

Sabine Brandt

Andrei Egorov

Ervin Fodor

David Howard Levy

Nicholas P Restifo

Mark R Krystal

Sumit K Chanda

John Young

Thomas Chambers

Michael Bergmann

Adolfo García-Sastre

Balaji Manicassamy

Qinshan Gao

David Kirkwood Clarke

Renate König

Frances Smith

Silke Stertz

Rong Hai

Jeffrey Parvin

Enami Masayoshi

Nicholas F Restifo

Natalie Pica

Dirk Eggink

Rafael A Medina-Silva

Joan Elizabeth Durbin

Richard J Webby

Provided herein are chimeric hemagglutinin (HA) polypeptides and uses thereof for inducing an immune response (e.g., an antibody response) against influenza virus. Also provided herein are methods of generating antibodies to the chimeric HA polypeptides in a subject.

Influenza virus hemagglutinin proteins and uses thereof

Described herein are chimeric Newcastle disease viruses comprising a packaged genome comprising a transgene encoding interleukin-12. The chimeric Newcastle disease viruses and compositions thereof are useful in combination with an antagonist of programmed cell death protein 1 ('PD-1') or a ligand thereof in the treatment of cancer. In particular, described herein are methods for treating cancer comprising administering the chimeric Newcastle disease viruses in combination with an antagonist of PD-1 or a ligand thereof, wherein the chimeric Newcastle disease virus comprises a packaged genome comprising a transgene encoding interleukin-12.

Newcastle disease viruses and uses thereof

Provided herein are antibodies that bind to neuraminidase (NA) of different strains of influenza B virus, host cells for producing such antibodies, and kits comprising such antibodies. Also provided herein are compositions comprising antibodies that bind to NA of different strains of influenza B virus and methods of using such antibodies to diagnose, prevent or treat influenza virus disease.

Anti-influenza B virus neuraminidase antibodies and uses thereof

Provided herein are immunization regimens for inducing an immune response (e.g., an antibody response) against influenza virus. In specific aspects, the immunization regimens involve the administration of a chimeric hemagglutinin (HA), a headless HA or another influenza virus stem domain based construct (e.g., the HA stem domain or a fragment thereof) to a subject. In certain aspects, the immunization regimens also involve the administration of an influenza virus neuraminidase immunogen.

Influenza virus vaccination regimens

Provided herein are chimeric influenza hemagglutinin (HA) polypeptides, compositions comprising the same, vaccines comprising the same, and methods of their use.

Influenza virus vaccines and uses thereof

Provided herein are antibodies that cross-react with hemagglutinin from strains of influenza virus of the same subtype or different subtypes, host cells for producing such antibodies, and kits comprising such antibodies. Also provided herein are compositions comprising antibodies that cross-react with hemagglutinin from strains of influenza virus of the same subtype or different subtypes and methods of using such antibodies to diagnose, prevent or treat influenza virus disease.

Antibodies against influenza virus hemagglutinin and uses thereof

The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations.

Genetically engineered swine influenza virus and uses thereof

The present invention provides chimeric negative-stand RNA viruses that allow a subject, e.g., an avian, to be immunized against two infectious agents by using a single chimeric virus of the invention. In particular, the present invention provides chimeric influenza viruses engineered to express and incorporate into their virions a fusion protein comprising an ectodomain of a protein of an infectious agent and the transmembrane and cytoplasmic domain of an influenza virus protein. Such chimeric viruses induce an immune response against influenza virus and the infectious agent. The present invention also provides chimeric Newcastle Disease viruses (NDV) engineered to express and incorporate into their virions a fusion protein comprising the ectodomain of a protein of an infectious agent and the transmembrane and cytoplasmic domain of an NDV protein. Such chimeric viruses induce an immune response against NDV and the infectious agent.

Chimeric viruses presenting non-native surface proteins and uses thereof

Described herein are chimeric Newcastle disease viruses engineered to express an agonist of a co-stimulatory signal of an immune cell and compositions comprising such viruses. Also described herein are chimeric Newcastle disease viruses engineered to express an antagonist of an inhibitory signal of an immune cell and compositions comprising such viruses. The chimeric Newcastle disease viruses and compositions are useful in the treatment of cancer. In addition, described herein are methods for treating cancer comprising administering Newcastle disease viruses in combination with an agonist of a co-stimulatory signal of an immune and/or an antagonist of an inhibitory signal of an immune cell.

Provided herein are influenza hemagglutinin stem domain polypeptides, compositions comprising the same, vaccines comprising the same and methods of their use.

Provided herein are flu hemagglutinin polypeptides, including chimeric influenza virus hemagglutinin polypeptides, and flu hemagglutinin polypeptides comprising modified glycosylation sites and non-naturally glycosylation sites, compositions comprising the same, vaccines comprising the same and methods of their use.

Growing community of inventors

Leonia, NJ, United States of America

Peter M Palese